ReviewNPJ precision oncology2022
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.
Review in NPJ precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Costs of mental health care resource use in people with obesity: A systematic review.PloS one · 2025Pooled it
- Determining the Causal Effect of Neurotrophic Tropomyosin Receptor Kinase Gene Fusions on Survival Prognosis for Adult Patients With Advanced Cancers.JCO precision oncology · 2026Article
- Action Plan to Better Approximate Reality in Cost-Effectiveness Analyses.Applied health economics and health policy · 2026Article
- Beyond CE Marking: The Need for Life-Cycle Health Technology Assessment of Medical Devices for Patient Safety and Health-System Value.Healthcare (Basel, Switzerland) · 2026Review
- Article
- Determining the Survival Impact and Cost-Effectiveness of Multi-Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches.Health services research · 2026Article
- Assessing real-world evidence utilization in oncology health technology assessments: insights from external control-arm studies.Oncology reviews · 2026Article
- National HTA system in Canada: From system analysis and understanding to system strengthening.PLOS global public health · 2026Article
- From product to knowledge: the life cycle of health technologies 2.0 as a framework for health system improvement.Frontiers in pharmacology · 2026Article
- Leveraging managed access with life-cycle reassessment in Asia-Pacific: advancing the learning of health system matters for innovative medicines in oncology.The Lancet regional health. Western Pacific · 2025Article
- Determining the value of genomics in healthcare.Nature medicine · 2025Review
- Article
- Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care.JCO precision oncology · 2025Article
- Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews.International journal of technology assessment in health care · 2025Article
- Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.Future oncology (London, England) · 2025Review
- How is Value Defined in Molecular Testing in Cancer? A Scoping Review.Applied health economics and health policy · 2025Article
- Conversational Agents to Support Pain Management: A Scoping Review.European journal of pain (London, England) · 2025Article
- Core variables for real-world clinicogenomic data collection in precision oncology.ESMO real world data and digital oncology · 2025Article
- Addressing immortal time bias in precision medicine: Practical guidance and methods development.Health services research · 2025Article
- How life-cycle real-world evidence can bridge evidentiary gaps in precision oncology.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advances are rapid, involve small patient groups, and are frequently evaluated without a randomized comparison group. In light of these challenges, mechanisms to manage precision oncology uncertainties are critical. We propose a life-cycle HTA framework and outline supporting criteria to manage uncertainties based on real world data collected from learning healthcare systems. If appropriately designed, we argue that life-cycle HTA is the driver of real world evidence generation and furthers our understanding of comparative effectiveness and value. We conclude that life-cycle HTA deliberation processes must be embedded into healthcare systems for an agile response to the constantly changing landscape of precision oncology innovation. We encourage further research outlining the core requirements, infrastructure, and checklists needed to achieve the goal of learning healthcare supporting life-cycle HTA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.